| All, N |
10 258 |
552 |
| Pimobendan prescription group, n |
473 |
276 |
| Non-prescription group, n |
9785 |
276 |
| Standardized mean difference (pimobendan prescription group–non-prescription group) |
| Age |
0.18 |
0.01 |
| Sex |
-0.26 |
0.05 |
| Interval between hospitalizations for heart failure |
0.13 |
0.09 |
| ADL score at discharge |
-0.15 |
0 |
| NYHA class |
0.19 |
0.08 |
| Underlying heart disease |
| Ischemic heart disease |
-0.24 |
0.01 |
| Cardiomyopathy |
-0.39 |
-0.03 |
| Valvular disease |
0 |
0.01 |
| Arrhythmia |
-0.25 |
0.01 |
| Other heart diseases |
0.01 |
0.04 |
| Information on hospital visit that served as the baseline for start of the follow-up period |
| Inpatient clinical department - Cardiology department |
-0.07 |
0.08 |
| Inpatient clinical department - Cardiovascular surgery |
0.09 |
0 |
| Inpatient clinical department–Others |
0.04 |
-0.04 |
| Discharge to home |
-0.08 |
-0.11 |
| Duration (days) spent in hospital |
-0.34 |
0.07 |
| Concomitant drugs and therapy receive during the hospital visit that served as the baseline for start of the follow-up period |
| Inotropic agents (intravenous injection) |
-0.56 |
-0.06 |
| Diuretics (intravenous injection) |
-0.01 |
0.02 |
| Tolvaptan |
-0.4 |
0.04 |
| Carperitide |
-0.13 |
0.08 |
| Concomitant drugs and therapy during follow-up |
| ACE-I and/or ARB |
0 |
0.06 |
| β blocker |
-0.39 |
-0.03 |
| Digitalis preparation |
-0.16 |
-0.05 |
| Diuretics (excluding tolvaptan and mineralocorticoid receptor antagonist) |
-0.27 |
0.03 |
| Tolvaptan |
-0.45 |
-0.07 |
| Mineralocorticoid receptor antagonist |
-0.28 |
-0.06 |
| Statin |
-0.07 |
0.18 |
| Nitrates |
-0.08 |
0.03 |
| Cardiac rehabilitation |
-0.08 |
-0.04 |
| Concomitant disease during the hospital visit that served as the baseline for start of the follow-up period |
| Atrial fibrillation |
-0.09 |
0.03 |
| Diabetes (including abnormal glucose tolerance) |
-0.17 |
-0.06 |
| Hypertension |
-0.23 |
0.13 |
| Dyslipidemia |
-0.21 |
0.15 |